For severe chronic rhinosinusitis with nasal polyps, novel stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid, the randomized CROWNS-2 trial showed.

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow ...

Rothschild & Co Redburn initiated coverage of Regeneron (REGN) with a Buy rating and $890 price target Published first on TheFly – the ultimate ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Regeneron (NASDAQ:REGN), a leading biotechnology firm known for its work in immunology and ophthalmology, reported Q2 2025 earnings on August 1, 2025.

REGENERON PHARMACEUTICALS (REGN): Free Stock Analysis Report This article Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines originally appeared on Benzinga.com ...

Regeneron is having difficulties again with a contract manufacturer, reporting the delay of two FDA regulatory decisions due this month for Eylea.

(RTTNews) - Regeneron Pharmaceuticals (REGN) announced earnings for second quarter that beat the Street estimates. The company's bottom line totaled $1.392 billion, or $12.81 per share. This ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand for its blockbuster eczema treatment, Dupixent, sending its ...

TARRYTOWN, N.Y., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2025 and provided a business update.